Claims for Patent: 10,786,478

Summary for Patent: 10,786,478

Title:	Methods of reducing the risk of cardiovascular events in a subject
Abstract:	In various embodiments, the present disclosure provides methods reducing the risk of cardiovascular events in a subject on statin therapy by administering to the subject a pharmaceutical composition comprising about 1 g to about 4 g of eicosapentaenoic acid ethyl ester or a derivative thereof.
Inventor(s):	Soni; Paresh (Mystic, CT)
Assignee:	Amarin Pharmaceuticals Ireland Limited (Dublin, IE)
Application Number:	16/736,936
Patent Claims:	1. A method of reducing risk of a third and further cardiovascular event in a subject with established cardiovascular disease and who has had a cardiovascular event, the method comprising administering to said subject about 4 g of ethyl icosapentate per day for a period effective to reduce the risk of the third and further cardiovascular event in the subject. 2. The method of claim 1, comprising administering about 4 g of ethyl icosapent ethyl per day to the subject to reduce a risk of a fourth cardiovascular event. 3. The method of claim 1, wherein the cardiovascular event is selected from the group consisting of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina. 4. The method of claim 1, wherein the subject is on statin therapy. 5. The method of claim 1, wherein the subject has a baseline triglyceride level of at least 135 mg/dL. 6. The method of claim 1, wherein the ethyl icosapentate comprises at least about 90 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 7. The method of claim 1, wherein the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 8. The method of claim 7, wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules. 9. The method of claim 1, wherein the established cardiovascular disease is determined by the presence of any one of: documented coronary artery disease, documented cerebrovascular disease, documented carotid disease, documented peripheral arterial disease, or combinations thereof. 10. A method of reducing risk of a second or further cardiovascular event in a subject, the method comprising administering to said subject about 4 g of ethyl icosapentate per day for a period effective to reduce the risk of the second or further cardiovascular event in the subject, wherein the subject has diabetes and at least one additional risk factor for cardiovascular disease. 11. The method of claim 10, where in the at least one additional risk factor for cardiovascular disease is selected from the group consisting of (a) a male gender of at least 55 years of age or a female gender of at least 65 years of age, (b) smokes cigarettes or has stopped smoking cigarettes within three months before administration of the composition, (c) blood pressure of at least 140 mmHg systolic or at least 90 mmHg diastolic, (d) on antihypertensive medication, (e) a male gender with HDL-cholesterol level 40 mg/dL or less or a female gender with HDL-cholesterol level 40 mg/dL or less, (f) has a hsCRP level of greater than 3 mg/L, (g) a creatine clearance between 30 mL/min and 60 mL/min, (h) has non-proliferative retinopathy, (i) pre-proliferative retinopathy, (j) proliferative retinopathy, (k) maculopathy, (l) advanced diabetic eye disease or a history of photocoagulation, (m) micro- or macro-albuminuria, and (n) a asymptomatic ankle-brachial index of less than 0.9. 12. The method of claim 10, wherein the subject has at least two additional risk factors for cardiovascular disease. 13. The method of claim 10, comprising administering about 4 g of ethyl icosapent ethyl per day to the subject to reduce a risk of a third cardiovascular event. 14. The method of claim 10, wherein the cardiovascular event is selected from the group consisting of cardiovascular death, myocardial infarction, stroke, coronary revascularization, and unstable angina. 15. The method of claim 10, wherein the subject is on statin therapy. 16. The method of claim 10, wherein the subject has a baseline triglyceride level of at least 135 mg/dL. 17. The method of claim 10, wherein the ethyl icosapentate comprises at least about 90 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 18. The method of claim 10, wherein the ethyl icosapentate comprises at least about 96 wt. % of all omega-3 fatty acids in the pharmaceutical composition. 19. The method of claim 18, wherein about 1 g of the pharmaceutical composition is present in each of 4 capsules.